Fluticasone Furoate
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Fluticasone Furoate |
| DrugBank ID | DB08906 |
| Brand Names (EU) | Avamys, Relvar Ellipta, Revinty Ellipta |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 99.98% |
Approved Indication (EMA)
Asthma Indication Revinty Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists. COPD Indication Revinty Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bron
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | atopic eczema | 99.98% | DL |
| 2 | allergic asthma | 99.98% | DL |
| 3 | intrinsic asthma | 99.97% | DL |
| 4 | bronchitis | 99.89% | DL |
| 5 | asthma | 99.88% | DL |
| 6 | 2-hydroxyethyl methacrylate sensitization | 99.87% | DL |
| 7 | dermatitis, atopic | 99.81% | DL |
| 8 | contact dermatitis | 99.46% | DL |
| 9 | asthma-related traits, susceptibility to | 99.37% | DL |
| 10 | occupational dermatitis | 99.33% | DL |
| 11 | phototoxic dermatitis | 99.12% | DL |
| 12 | obstructive lung disease | 98.90% | DL |
| 13 | polyp of vocal cord | 98.87% | DL |
| 14 | polyp of middle ear | 98.86% | DL |
| 15 | fibroepithelial polyp | 98.84% | DL |
| 16 | seborrheic dermatitis | 98.83% | DL |
| 17 | neoplastic polyp | 98.82% | DL |
| 18 | atopic dermatitis | 98.82% | DL |
| 19 | polyp of vulva | 98.81% | DL |
| 20 | polyp of frontal sinus | 98.81% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.